Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as [14C]-LY3549492
LY3549492 · 5 trials · 6 indications
A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module
A summary of treatment emergent adverse events (TEAEs), SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.
A summary of TEAEs and SAEs regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY3549492 Dose 1 | EXPERIMENTAL | Participants will receive LY3549492 orally |
| LY3549492 Dose 2 | EXPERIMENTAL | Participants will receive LY3549492 orally |
| LY3549492 Dose 3 | EXPERIMENTAL | Participants will receive LY3549492 orally |
| LY3549492 Dose 4 | EXPERIMENTAL | Participants will receive LY3549492 orally |
| LY3549492 Dose 5 | EXPERIMENTAL | Participants will receive LY3549492 orally |
| Placebo | PLACEBO_COMPARATOR | Participants will receive Placebo orally |
| LY3549492 (Treatment Group 1) | EXPERIMENTAL | LY3549492 administered orally. |
| LY3549492 (Treatment Group 2) | EXPERIMENTAL | LY3549492 administered orally. |
| LY3549492 (Treatment Group 3) | EXPERIMENTAL | LY3549492 administered orally. |
| LY3549492 (Treatment Group 4) | EXPERIMENTAL | LY3549492 administered orally. |
| LY3549492 Part A | EXPERIMENTAL | LY3549492 administered orally |
| LY3549492 Part B | EXPERIMENTAL | LY3549492 administered orally |
| Placebo Part A | PLACEBO_COMPARATOR | Placebo administered orally |
| Placebo Part B | PLACEBO_COMPARATOR | Placebo administered orally |
| LY3549492 (Part A) | EXPERIMENTAL | LY3549492 administered orally as multiple ascending doses. |
| Placebo (Part A) | PLACEBO_COMPARATOR | Placebo administered orally. |
| LY3549492 + Midazolam + Atorvastatin (Part B) | EXPERIMENTAL | LY3549492 coadministered orally with midazolam and atorvastatin. |
| Placebo + Midazolam + Atorvastatin (Part B) | PLACEBO_COMPARATOR | Placebo coadministered orally with midazolam and atorvastatin. |
| Name | Type | Description |
|---|---|---|
| LY3549492 | DRUG | Administered orally |
| Placebo | DRUG | Administered orally |
| Atorvastatin | DRUG | Administered orally. |
| Midazolam | DRUG | Administered orally. |
Inclusion Criteria: W8M-MC-GN01: * Assigned male at birth * Assigned female at birth, who are of non-childbearing potential W8M-MC-CWMM: * Have a BMI of * ≥ 30 kilograms per square meter (kg/m²) or * ≥ 27 kg/m² and \< 30 kg/m² with at least one weight-related comorbidity * Have had a stable...
Top 20 of 35 competitors
LY3549492 is an investigational small molecule developed by Eli Lilly and Company for metabolic conditions, specifically type 2 diabetes and obesity or overweight. It is being studied in clinical trials and is not yet approved for any indication. Lilly is evaluating it in both healthy participants and people with type 2 diabetes or excess weight.
LY3549492 is being studied for the treatment of type 2 diabetes mellitus and for weight management in adults with obesity or overweight. These are investigational uses only. Clinical trials have enrolled participants with type 2 diabetes in China and Japan, and participants with obesity or overweight in the United States.
LY3549492 is developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the clinical program evaluating the compound in type 2 diabetes and obesity or overweight.
LY3549492 is in clinical development. Phase 1 studies have been completed in healthy participants and in participants with type 2 diabetes, and a Phase 2 study in adults with obesity or overweight has also been completed. The drug remains investigational and has not been approved by the FDA.
Completed trials include NCT07232732 in healthy participants and participants with overweight or obesity, NCT07073170 in Chinese participants with type 2 diabetes, NCT06869018 in Japanese participants with type 2 diabetes and healthy Japanese participants, and the Phase 2 weight management study NCT06683508 in adults with obesity or overweight.
Yes. [14C]-LY3549492 is an alternative name for LY3549492, referring to a carbon-14 labeled form of the same compound used in research settings. Both names refer to the Eli Lilly small molecule being studied in type 2 diabetes and obesity or overweight.